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Abstract: The therapeutic utilization of stem cells has been ongoing for several decades, 
principally in the form of bone marrow (BM) transplants to treat various hematological disorders 
and other immune-related diseases. More recently, stem cells have been examined as a potential 
therapy for a multitude of other diseases and disorders, many of which are currently untreatable. 
One consideration that poses a formidable task for the successful clinical application of stem 
cells in new disease models is the impact of the host tissue microenvironment on the desired 
therapeutic outcome. In vitro, stem cells exist in surroundings directly controllable by the 
researcher to produce the desired cellular behavior. In vivo, the transplanted cells are exposed 
to a dynamic host microenvironment laden with soluble mediators and immunoreactive cells. 
In this review, we focus on the possible contribution by microenvironmental factors, and how 
these inﬂ  uences can be overcome in therapies utilizing mesenchymal stem cells (MSCs), such 
as for graft versus host disease, multiple sclerosis and ischemia among others. Speciﬁ  cally, 
we examine three ubiquitous microenvironmental factors, IL-1α/β, TNFα, and SDF-1α, and 
consider how inhibitors and receptor antagonists to these molecules could be applied to increase 
the efﬁ  cacy of MSC therapies while minimizing unforeseen harm to the patient.
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Introduction
The emergence of stem cells as a therapeutic for many diseases, disorders and injuries 
has brought excitement among scientists, clinicians and patients alike regarding the 
potential treatment of previously untreatable conditions. However, the implementation 
of many stem cell therapies in patients may still be years away. When considering 
translating these therapies into patients, there are two principal concerns that must be 
resolved: I. Can the stem cells efﬁ  ciently produce the desired therapeutic outcome, 
albeit tissue replacement or repair, in vitro?; and II. Can the in vitro studies be replicated 
in vivo, both short- and long-term, with increased conﬁ  dence? Much of the past research 
has concentrated on question one, or more appropriately, the philosophy of can we 
apply the method? However, to recognize stem cells as key factors in the treatment of 
various ailments, we need to rest assured that we can also answer question two – Is this 
a viable treatment approach? These questions are aside from the ethical implications 
surrounding the ﬁ  eld, which ask should we do it.
In any case, stem cells will continue to be researched as a potential treatment 
for a multitude of diseases and disorders. Considerable progress has been made in 
addressing the ﬁ  rst question stated above – can we do it. A vast number of tissue types 
have been generated from both embryonic (ES cells) and adult stem cells. ES cells 
are pluripotent cells derived from the inner cell mass of the blastocyst, which hold 
tremendous potential in generating speciﬁ  ed tissue types (Lerou and Daley 2005). Biologics: Targets & Therapy 2008:2(4) 700
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However, the potential for immune rejection, together with 
the possibility of tumor formation has caused their application 
in humans to proceed with caution (Lerou and Daley 2005). 
Adult stem cells tend to be tissue-speciﬁ  c cells with limited 
differentiation potential compared with ES cells. Adult stem 
cells are clinically attractive therapies due to their reduced 
risk of tumorigenesis and ability to expand with relative ease 
(Cheng et al 2004).
Among the many types of adult stem cells, those resident 
to the bone marrow (BM), particularly mesenchymal stem 
cells (MSCs), have gained extensive interest among scien-
tists and clinicians (Deans and Moseley 2000). MSCs are 
mesodermal cells primarily resident to the adult BM, which 
undergo lineage-speciﬁ  c differentiation to generate bone, 
fat, and cartilage among other tissue types (Bianco et al 
2001). MSCs have also been reported to transdifferentiate 
into deﬁ  ned ectodermal and endodermal tissues in vitro, 
thus alluding to their inherent plasticity (Choi and Panayi 
2001; Cho et al 2005; Eberhardt et al 2006; Ong et al 2006; 
Greco and Liu et al 2007; Greco and Zhou et al 2007; Jeon 
et al 2007; Trzaska et al 2007). MSCs are available for 
autologous therapies, have a unique ability to bypass immune 
rejection and are inherently migratory (Potian et al 2003). 
These properties of MSCs make them particularly well suited 
when considering the second question posed earlier – can in 
vitro ﬁ  ndings be accurately recapitulated in vivo? Whereas 
tissues derived from ES cells or other types of stem cells may 
be rejected when transplanted, MSCs offer the potential for 
allogeneic transplantation and a readily available source of 
“off-the-shelf” stem cells for personalized therapies.
However, the unique immune properties of MSCs do not 
guarantee that the cells will produce the desired therapeutic 
outcome or even that they will not be rejected. In vitro, 
a MSC’s growth conditions can be closely monitored to 
favor stem cell growth and/or differentiation. In vivo, the 
transplanted MSCs are exposed to local immune cells and 
soluble mediators that could inﬂ  uence the cells’ behavior, 
either positively or negatively regarding the desired outcome. 
This concept of the tissue microenvironment has become a 
growing concern among researchers, and may be the ultimate 
factor in deciding whether a stem cell therapy succeeds or 
fails (Greco et al 2004; Yan et al 2006; Grassel and Ahmed 
2007; Phinney and Prockop 2007).
A prototypical example of a tissue microenvironment 
affecting stem cell behavior is observed among hematopoietic 
stem cells (HSCs) and their niche within the BM. HSCs are 
relatively quiescent cells located close to the BM endosteum 
at relatively low oxygen concentration (Greco et al 2004). 
As HSCs differentiate, the maturing immune cells migrate 
towards the central sinus of the BM under progressively 
higher oxygen concentrations (Greco et al 2004). The change 
in oxygen is a key determinant in the maturation of the 
immune cells before they leave the BM and migrate into the 
peripheral circulation (Greco et al 2004). In contrast, MSCs 
are located close to trabecular bone near the central sinus 
of the BM (Bianco et al 2001). As MSCs migrate towards 
the endosteum under progressively lower concentrations of 
oxygen, the stem cells differentiate into stromal ﬁ  broblasts, 
which form the principal support structure for immune cell 
maturation (Bianco et al 2001).
This example demonstrates that local microenvironmental 
changes in variables such as oxygen concentration can 
drastically affect the behavior of MSCs. Since MSCs have 
been shown to generate a vast number of tissues, they have 
clinical implications in a wide array of diseases and disorders. 
Among possible transplantation sites are tissues such as cardiac, 
neural, pancreatic and bone. Each tissue provides a unique local 
microenvironment that can affect the success of the therapy. 
The problem facing researchers is accurately developing in 
vitro models to recapitulate the tissue microenvironment so 
that cellular behavior can be observed prior to transplantation. 
This is no easy task considering the dynamic nature of the 
microenvironment.
Transplantation of MSCs alone will generate a local 
immune response and disrupt homeostasis within the tissue 
milieu by causing release of inﬂ  ammatory mediators, such as 
cytokines. The anatomy of the BM is such that MSCs are in 
direct interaction with immune cells and form synapse-like 
structures with innervating nerve ﬁ  bers (Bianco et al 2001). 
MSCs express receptors for many cytokines and neurotrans-
mitters, thus demonstrating their potential to respond to local 
microenvironmental changes (Greco and Rameshwar 2007). 
Excessive cytokine release within the transplantation site 
could lead to the production of other soluble factors by the 
MSCs themselves. If these factors are immunoreactive, then 
other immune cells could inﬁ  ltrate the tissue and cause an 
exacerbated immune response, rejection of the transplant or 
differentiation of the MSCs (Figure 1A). On the other hand, 
MSCs have been shown to be a potent source of trophic 
factors (Phinney and Prockop 2007). These ﬁ  ndings indicate 
that MSCs could also be used to aid normal tissue repair, 
perhaps even more so than in cell replacement. Whether 
transplanted MSCs cause an immune insult or help repair 
injured tissues may be difﬁ  cult to determine unless appro-
priate models are developed to better predict the outcome. 
However, if MSCs are found to negatively impact the host Biologics: Targets & Therapy 2008:2(4) 701
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microenvironment through exposure to soluble mediators, 
there are still potential methods to develop effective 
therapeutics. When considering the example presented in 
Figure 1A, inclusion of speciﬁ  c cytokine receptor antago-
nists or inhibitors could suppress the untoward effects of 
the host microenvironment on the transplanted MSCs, 
thus leading to deﬁ  ned therapeutic outcomes (Figure 1B). 
Throughout the remainder of this review, we will address 
the feasibility of using similar pharmacologic approaches 
in MSC transplants, while focusing on three ubiquitous 
microenvironmental factors: IL-1α/β, TNFα, and SDF-1α. 
Speciﬁ  cally, we will examine how receptor antagonists or 
inhibitors to these factors, whether federally approved or in 
development, may limit the potential negative inﬂ  uences of 
the tissue microenvironment.
Interleukin-1α/β
IL-1α and IL-1β are members of the IL-1 superfamily 
of cytokines. These pro-inﬂ  ammatory mediators are primar-
ily synthesized by macrophages, monocytes and dendritic 
cells, and are responsible for immune defense against 
infection (Table 1) (Dinarello 1994). IL-1α and IL-1β are 
also key regulators of hematopoesis and the inﬂ  ammatory 
process (Table 1) (Dinarello 1994). Both cytokines are found 
throughout the body, thus they are expected to be present 
within the local microenvironment of most tissues.
Our laboratory has previously demonstrated that MSCs 
express IL-1RI, which is the principal receptor for both 
IL-1α and IL-1β (Greco and Rameshwar 2007). Interest-
ingly, membrane expression of the receptor was maintained 
throughout the course of transdifferentiation of MSCs into 
functional neurons (Greco and Rameshwar 2007). If IL-1α or 
IL-1β were found to have negative effects on MSCs, then these 
effects may also be seen on transplantable tissues differentiated 
from MSCs. These results have implications regarding the 
ideal stage of stem cell implantation, whether undifferentiated, 
partly differentiated or fully differentiated.
IL-1α was found to alter the behavior of undifferentiated 
MSCs and neurons differentiated from MSCs (Greco 
and Rameshwar 2007). Speciﬁ  cally, stimulation of MSCs 
A. B.
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Figure 1 Cartoon depicting the potential effects of an inﬂ  ammatory microenvironment on mesenchymal stem cell (MSC) therapies. A. An injured tissue, such as a bone 
fracture, is laden with inﬂ  ammatory cytokines, such as IL-1α, IL-1β, TNFα, or IL-6, within the microenvironment. MSCs introduced into the microenvironment can respond to 
the inﬂ  ammatory stimuli by synthesizing and releasing immunoreactive factors, such as substance P (SP) or other neuropeptides. Excessive production of SP would lead to an 
exacerbated immune response and inﬁ  ltration of additional immune cells into the injured tissue. Additionally, the inﬂ  ammatory stimuli could have an untoward effect on MSC 
differentiation, for example differentiation into ﬁ  broblasts rather than osteoblasts. B. Alternatively, delivery of MSCs together with an inﬂ  ammatory cytokine antagonist/inhibitor 
may abrogate immunoreactivity and allow the desired stem cell therapeutic to proceed unhindered.Biologics: Targets & Therapy 2008:2(4) 702
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with IL-1α caused production of the neurotransmitter, 
substance P (SP), by undifferentiated and differenti-
ated cells (Greco and Rameshwar 2007). Similar effects 
were not observed in cells stimulated with IL-1β (Greco 
and Rameshwar 2007). SP has involvement in various 
physiological functions, such as the perception of pain and 
breast cancer progression, however the peptide also has a 
stimulatory effect on immune cell development and function 
(Greco et al 2004). SP was also found to stabilize IL-1RI 
mRNA, thus potentially forming an autocrine feedback loop 
whereby IL-1α present in the microenvironment continually 
stimulates production of SP by the MSCs or their differenti-
ated progeny (Greco and Rameshwar 2007). The excessive 
levels of SP could lead to immune cell inﬁ  ltration and an 
exacerbated immune response, which may cause rejection 
of the transplant.
Interestingly, IL-1α also had a more global effect on the 
behavior of MSCs, speciﬁ  cally their ability to transdifferenti-
ate into neurons (Greco and Rameshwar 2007). MSCs that 
were grown in neuronal induction media containing IL-1α 
showed greater expression of genes linked to neurogen-
esis compared to cells induced without IL-1α (Greco and 
Rameshwar 2007). In comparison to the deleterious effects 
of IL-1α mentioned above, these results demonstrate what 
appears to be a positive effect on MSC differentiation. If the 
desired therapeutic value of MSCs is transdifferentiation, in 
this case into neurons, then this ﬁ  nding can be considered 
beneﬁ  cial. However, in many cases, the maintenance of 
MSCs as stem cells will be desired. Hence, the inﬂ  uence of 
the microenvironment on premature MSC differentiation 
would be unwarranted.
To counter the negative effects of IL-1α present 
within a tissue microenvironment, co-therapies utilizing 
MSCs and speciﬁ  c IL-1R antagonists or inhibitors may 
be successful. The IL-1R antagonist (IL-1ra) is naturally 
occurring and binds to the IL-1RI. IL-1ra competes for 
binding to the IL-1RI with IL-1α and IL-1β, however 
binding of this ligand does not result in an intracellular 
signal (Dinarello 1994). A commercially available IL-1RI 
antagonist is Kineret®, also known as Anakinra®, which is 
a recombinant, non-glycosolated version of human IL-1ra 
(Table 1) (Hannum et al 1990; Arend 1993; Bresnihan and 
Cunnane 1998; Gabay 2000). The drug has been used in the 
treatment of inﬂ  ammatory conditions such as rheumatoid 
arthritis.
Recent studies in mice have shown that MSCs have 
an inherent ability to counteract the deleterious inﬂ  amma-
tory effects of IL-1α in injured tissues (Ortiz et al 2007). 
In response to bleomycin-induced inﬂ  ammation and ﬁ  brosis 
within the lungs of mice, transplanted MSCs were shown to 
synthesize IL-1ra to neutralize microenvironmental IL-1α. 
In addition, MSCs also protected the tissue from further 
damage by inhibiting the production of TNFα within the 
lung. If, however, exogenous IL-1ra supplementation is 
also necessary, it may be possible to administer an IL-1ra, 
such as Anakinra®, during MSC transplantation. However, 
the means of accurately delivering the drug to its target is 
unknown. Perhaps the drug could be bound to the MSCs 
Table 1 Microenvironmental factors implicated in the outcome of MSC therapies
Cytokine/
chemokine
Source Physiological 
function
Receptor 
expression 
on MSCs
Inhibitors/
antagonists
Reference
IL-1α/β macrophages, 
monocytes, 
dendritic cells
immune response, 
inﬂ  ammation, 
hematopoiesis
yes IL-1ra, Kineret® Bresnihan and Cunnane 
1998; Gabay 2000; Arend 
1993; Hannum et al 1990
TNFα macrophages immune response, 
inﬂ  ammation, 
proliferation, 
differentiation, 
tumorigenesis, 
viral replication
yes Remicade®, 
Humira®, Enbrel®
Knight et al 1993; Choy 
and Panayi 2001
SDF-1α tissue-speciﬁ  c 
stromal cells
immune response, 
inﬂ  ammation, 
hematopoiesis, 
chemotaxis, 
tumor metastasis
yes Mozobil®, T134, 
tannic acid
Cashen et al 2007; 
Arakaki et al 1999; Chen 
et al 2003
Notes: Listed microenvironmental factors are ubiquitously expressed throughout the body and have known effects on mesenchymal stem cells MSCs. Co-therapy with 
pharmacologics, such as receptor antagonists or speciﬁ  c inhibitors, may improve the desired therapeutic outcome.Biologics: Targets & Therapy 2008:2(4) 703
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in such a way that the stem cells actually “piggy-back” the 
drug to the target. A great deal of research is still necessary 
to develop these types of therapeutics.
Tumor necrosis factor α
TNFα is a pro-inflammatory cytokine principally 
synthesized by macrophages, which is involved in the acute 
phase of systemic inﬂ  ammation (Locksley et al 2001). 
More speciﬁ  cally, TNFα mediates immune cell homing, 
proliferation and differentiation, as well as tumorigen-
esis and viral replication (Table 1) (Locksley et al 2001). 
TNFα is ubiquitously found throughout the body, and 
is another important factor present within local tissue 
microenvironments.
We have previously demonstrated that MSCs express the 
principal receptor for TNFα, TNF-R1 (Table 1) (Greco and 
Rameshwar 2007). Similar to IL-1RI expression, TNF-RI 
levels were maintained during the entire course of MSC 
transdifferentiation into neurons (Greco and Rameshwar 
2007). However, whereas IL-1α was able to induce 
SP production in undifferentiated, partly differentiated and 
fully differentiated cells, TNFα had similar effects only in 
partly and fully differentiated cells (Greco and Rameshwar 
2007). Additionally, TNFα did not have the same enhancing 
effect on MSC transdifferentiation as IL-1α. These results 
re-emphasize that the ideal stage of differentiation for 
efﬁ  cient transplantation is unknown. In the case of exposure 
to microenvironmental TNFα, little to no negative effects 
may be observed with undifferentiated MSCs, while an 
exacerbated immune response may be seen if transplanting 
partly or fully transdifferentiated cells.
Recent studies have shown that undifferentiated MSCs 
incubated with TNFα have a greater ability to migrate in the 
presence of chemokines compared to cells incubated without 
TNFα (Ponte et al 2007; Schmal et al 2007). Increased 
chemotaxis of MSCs would be clinically important if proper 
homing to the site of tissue injury became more efﬁ  cient. 
However, since MSCs are inherently chemotactic, increased 
sensitivity to chemokine gradients could cause continuous 
mobilization within a tissue, and impede proper homing and 
delivery of the desired therapeutic.
To offset any deleterious effects of microenvironmental 
TNFα on proper homing of MSCs to the site of tissue 
injury, co-thereapies with existing TNFα inhibitors may 
be beneﬁ  cial. Currently there are three approved TNFα 
inhibitors, inﬂ  iximab (Remicade®), adalimumab (Humira®) 
and etanercept (Enbrel®), which are primarily used to 
treat inﬂ  ammatory and autoimmune disorders (Table 1) 
(Knight et al 1993; Choy and Panayi 2001). Inﬂ  iximab and 
adalimumab are monoclonal antibodies that bind TNFα and 
block signaling through the TNF-RI. Etanercept is a large 
molecular weight, soluble recombinant TNFα receptor 
fusion protein that binds TNFα and prevents signaling 
through membrane-bound TNF-RI. Administration of 
these pharmacologics in combination with MSC therapies 
may negate any untoward effects of TNFα on the desired 
therapeutic outcome.
Stromal cell-derived factor-1α
SDF-1α, also known as CXCL12, is a chemokine produced 
by stromal ﬁ  broblasts, which mediates inﬂ  ammation and 
the immune response through modulating lymphocyte 
chemotaxis (Table 1) (Bleul et al 1996). Additionally, 
SDF-1α regulates hematopoeisis and has a role in tumor 
metastasis (Table 1) (Bleul et al 1996). Like IL-1α/β and 
TNFα, SDF-1α is ubiquitously found throughout the 
body, and is an important soluble mediator of the tissue 
microenvironment.
Within the BM, the primary lineage-speciﬁ  c progeny 
of MSCs are stromal ﬁ  broblasts (Deans and Moseley 2000; 
Bianco et al 2001). It is not surprising then that SDF-1α is 
important in the biology of MSCs. Expression of the principal 
SDF-1α receptor, CXCR4, has been demonstrated on MSCs, 
where it has been shown to mediate site-directed homing of 
MSCs in models of tissue engineering (Schantz et al 2007). 
In the BM, SDF-1α is vital to the hematopoietic supportive 
function that MSCs exert to maintain proper hematopoeisis 
(Van Overstraeten et al 2006).
As mentioned earlier, preconditioning MSCs with 
cytokines such as IL-1β and TNFα increased the migratory 
capacity of the cells (Ponte et al 2007; Schmal et al 2007). 
However, these enhancing effects were shown to be 
independent of SDF-1α, and were instead mediated by other 
chemokines (Ponte et al 2007).
In general, the clinical relevance of SDF-1α in the success 
of MSC therapies is positive, since SDF-1α gradients help 
MSCs home to sites of tissue injury (Bleul et al 1996). 
In theory, MSCs could be administered systemically and 
allowed to respond to SDF-1α gradients for proper delivery to 
the target tissue. Once at the site of injury, MSCs themselves 
could serve as a source of SDF-1α (Zhang et al 2007). 
Expression of SDF-1α by MSCs has been shown to promote 
survival of cardiac myocytes after myocardial infarction in 
rats (Zhang et al 2007).
However, SDF-1α is also a potent lymphocyte chemoat-
tractant (Bleul et al 1996). Excess production of SDF-1α Biologics: Targets & Therapy 2008:2(4) 704
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within the microenvironment could potentially lead to 
increased immune cell inﬁ  ltration and transplant rejection. 
SDF-1α may be less beneficial or even deleterious in 
therapies transplanting cells partly or fully differentiated from 
MSCs. For instance, SDF-1α has been shown to increase 
the proliferation of neural progenitor cells dissociated from 
rat cortex (Gong et al 2006). Comparing these results to the 
example of MSC neuronal transdifferentiation discussed 
throughout this review, excess SDF-1α might impede the 
ﬁ  nal steps of neuronal maturation necessary for therapeutic 
improvement.
To counteract any negative influences of local 
microenvironmental SDF-1α on MSC therapies, there are 
several available pharmacologics that inhibit the SDF-1α/
CXCR4 interaction. Plerixafor, also known as Mozobil® or 
AMD3100, is a partial antagonist of CXCR4, which has 
recently competed Phase 3 clinical trials, but is not yet in 
routine clinical use (Table 1) (Cashen et al 2007). Current 
in vivo studies have shown that pre-treatment of MSCs with 
AMD3100 signiﬁ  cantly prevented stem cell migration to 
the injured rat brain (Wang et al 2007). Similar approaches 
may be beneﬁ  cial in order to prevent non-speciﬁ  c MSC 
migration. T134, a small molecule CXCR4 inhibitor, 
and tannic acid, a water-soluble polyphenol widely 
distributed within the plant kingdom that acts as a selec-
tive CXCR4 antagonist, both inhibit the SDF-1α/CXCR4 
interaction and may have future application as approved 
pharmacologics (Table 1) (Arakaki et al 1999; Chen et al 
2003). Administration of these compounds would most 
likely have to be locally delivered to the target tissue, since 
systemic inhibition of SDF-1α/CXCR4 could disrupt BM 
homeostasis or lead to excessive HSC mobilization into the 
peripheral circulation.
Summary
In this review, we address the concept of the tissue micro-
environment, and examine its clinical importance in MSC 
therapies. By accurately developing in vitro models that 
mimic the local tissue milieu, the behavior of MSCs or 
their differentiated progeny can be observed prior to in 
vivo application. Through like approaches, ill effects from 
soluble mediators or other cell types, which can impede 
the desired therapeutic outcome, can be assessed. In many 
cases, co-therapy with a pharmacologic such as a cytokine 
receptor antagonist may negate the deleterious effects of the 
microenvironment and optimize the therapeutic potential of 
MSCs. Here, we have focused on three ubiquitous microen-
vironmental factors with known effects on MSC function, 
and addressed how local delivery of inhibitors to these factors 
could improve the MSC therapy.
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